Standout Papers
Citation Impact
Citing Papers
Vertebral Fracture Assessment (VFA) With a Densitometer Predicts Future Fractures in Elderly Women Unselected for Osteoporosis
2008
Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130
2002 StandoutNobel
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
1998
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
2009 Standout
Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention
2012
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
2015
FRAX™ and the assessment of fracture probability in men and women from the UK
2008 Standout
Role of vesicular trafficking in skeletal dynamics
2014
Clinician’s Guide to Prevention and Treatment of Osteoporosis
2014 Standout
Updated fracture incidence rates for the US version of FRAX®
2009
UK clinical guideline for the prevention and treatment of osteoporosis
2017
Cancer treatment and survivorship statistics, 2022
2022 Standout
Healthcare Use among U.S. Women Aged 45 and Older: Total Costs and Costs for Selected Postmenopausal Health Risks
1999
Gene expression profiling predicts clinical outcome of breast cancer
2002 StandoutNature
Endogenous human microRNAs that suppress breast cancer metastasis
2008 StandoutNature
Thiazolidinediones
2004 Standout
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary
2010
Osteoporosis
2019 Standout
Bazedoxifene for the prevention of postmenopausal osteoporosis
2008
Efficacy of Raloxifene on Vertebral Fracture Risk Reduction in Postmenopausal Women with Osteoporosis: Four-Year Results from a Randomized Clinical Trial
2002
Osteoporosis
2006
Fracture healing in the elderly patient
2006
Parathyroid Hormone (1-34)-Coated Microneedle Patch System: Clinical Pharmacokinetics and Pharmacodynamics for Treatment of Osteoporosis
2010
Control of osteoblast function and regulation of bone mass
2003 Nature
Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene<SUBTITLE>Results From a 3-Year Randomized Clinical Trial</SUBTITLE>
1999 Standout
Identification of a Hormone-regulated Dynamic Nuclear Actin Network Associated with Estrogen Receptor α in Human Breast Cancer Cell Nuclei
2010
Distinct β-Arrestin- and G Protein-dependent Pathways for Parathyroid Hormone Receptor-stimulated ERK1/2 Activation
2006 StandoutNobel
Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
1999 Standout
Effect of Calcium and Vitamin D Supplementation on Bone Density in Men and Women 65 Years of Age or Older
1997 Standout
Primary Care for Survivors of Breast Cancer
2000
Cancer Metastasis: Building a Framework
2006 Standout
Prognostic utility of a semiquantitative spinal deformity index
2005
Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes<SUBTITLE>The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial</SUBTITLE>
2006
The Protective Effects of Estrogen on the Cardiovascular System
1999 Standout
Calcimimetics and calcilytics—fooling the calcium receptor
2005
Understanding and Communicating the Benefits and Risks of Denosumab, Raloxifene, and Teriparatide for the Treatment of Osteoporosis
2013
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
2000
Recurrence Rates after Treatment of Breast Cancer with Standard Radiotherapy with or without Additional Radiation
2001 Standout
Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis
2003
Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: The ACTIVE phase 3 trial
2016
Impracticability of Informed Consent in the Registry of the Canadian Stroke Network
2004 Standout
Targeted Regeneration of Bone in the Osteoporotic Human Femur
2011
Osteoporosis in chronic kidney disease
2004
Pharmacology of bisphosphonates
2011
Bone Quality — The Material and Structural Basis of Bone Strength and Fragility
2006 Standout
Osteoporosis: now and the future
2011 Standout
Hormone Replacement Therapy and Prevention of Nonvertebral Fractures
2001
Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures
2004
The Effect of Raloxifene Treatment in Postmenopausal Women with CKD
2008
Biological Functions of Autophagy Genes: A Disease Perspective
2019 Standout
Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture
2004
Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial
2001
Osteoporosis in men: Epidemiology, diagnosis, prevention, and treatment
2004
Four-month treatment with GLP-2 significantly increases hip BMD
2009
Does bone resorption inhibition affect the anabolic response to parathyroid hormone?
2004
PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase‐3β in osteoblastic Saos‐2 cells
2007 StandoutNobel
Contribution of Raloxifene and Calcium and Vitamin D3Supplementation to the Increase of the Degree of Mineralization of Bone in Postmenopausal Women
2003
Parathyroid hormone: past and present
2005
Nuclear actin polymerization is required for transcriptional reprogramming of Oct4 by oocytes
2011 StandoutNobel
A systematic review of diagnostic accuracy of vertebral fracture assessment (VFA) in postmenopausal women and elderly men
2016
Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene
2004
Mechanisms Involved in Skeletal Anabolic Therapies
2006
PHOSPHORUS METABOLISM AND MANAGEMENT IN CHRONIC KIDNEY DISEASE: Renal Osteodystrophy, Phosphate Homeostasis, and Vascular Calcification
2007
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
2017
Imminent fracture risk
2017
The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis
2003
Assessing the Risk of Breast Cancer
2000
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Type I collagen is a genetic modifier of matrix metalloproteinase 2 in murine skeletal development
2007
Practical considerations in PTH testing
2005
Endocrine Regulation of Energy Metabolism by the Skeleton
2007 Standout
The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
2013
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
2009 Standout
Osteoclast differentiation and activation
2003 StandoutNature
Comparative Analysis of the Radiology of Osteoporotic Vertebral Fractures in Women and Men: Cross-Sectional and Longitudinal Observations from the Canadian Multicentre Osteoporosis Study (CaMos)
2017
The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen
1998 Standout
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
2006
Resolution of Bisphosphonate-Associated Osteonecrosis of the Mandible: Possible Application for Intermittent Low-Dose Parathyroid Hormone [rhPTH(1-34)]
2007
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
2007
Regulation of bone mass by Wnt signaling
2006
Similarities and distinctions in the mode of action of different classes of antioestrogens.
2000
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Néstor–Guillermo progeria syndrome: A novel premature aging condition with early onset and chronic development caused by BANF1 mutations
2011
Endothelial function, vascular reactivity and gender differences in the cardiovascular system
2002
Prevention of Bone Loss in Renal Transplant Recipients
2003
The Impact of Monitoring on Adherence and Persistence with Antiresorptive Treatment for Postmenopausal Osteoporosis: A Randomized Controlled Trial
2004
No trend toward a spontaneous improvement of hyperparathyroidism and high bone turnover in normocalcemic long-term renal transplant recipients
1997
The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis
2003
Raloxifene to Prevent Gonadotropin-Releasing Hormone Agonist-Induced Bone Loss in Men with Prostate Cancer: A Randomized Controlled Trial
2004
Production and Actions of Estrogens
2002 Standout
Emerging therapeutic concepts for muscle and bone preservation/building
2015
The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis
2004
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
2001 Standout
The Hallmarks of Aging
2013 Standout
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
The Assessment of Fracture Risk
2010
Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone Diseases
2008
The Calcium-Sensing Receptor: Physiology, Pathophysiology and Car-Based Therapeutics
2007
Treatment of Breast Cancer
1998
Risedronate Rapidly Reduces the Risk for Nonvertebral Fractures in Women with Postmenopausal Osteoporosis
2004
Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress
2005 Standout
Osteoclast-derived activity in the coupling of bone formation to resorption
2005
Osteoporosis: burden, health care provision and opportunities in the EU
2011
Biomechanics of Bone: Determinants of Skeletal Fragility and Bone Quality
2002
Effects of teriparatide versus alendronate for treating glucocorticoid‐induced osteoporosis: Thirty‐six–month results of a randomized, double‐blind, controlled trial
2009
Parathyroid hormone and parathyroid hormone-related peptide, and their receptors
2004
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice
2003
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
2016
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Side Effects of Adjuvant Treatment of Breast Cancer
2001
Mechanisms of Anabolic Therapies for Osteoporosis
2007
Preservation of Fertility in Patients with Cancer
2009 Standout
Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment
2006
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
2017 Standout
Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women
2009
Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal Women
1998
Cancer of the Ovary
2004 Standout
Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis
2010
American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016
2016
Antiestrogenic Action of Raloxifene and Tamoxifen: Today and Tomorrow
1998
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Femoral bone loss progresses with age: A longitudinal study in women over age 65
1994
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Considerations for Development of Surrogate Endpoints for Antifracture Efficacy of New Treatments in Osteoporosis: A Perspective
2008
Diagnosis of Osteoporotic Vertebral Fractures: Importance of Recognition and Description by Radiologists
2004
Bone Response to Intermittent Parathyroid Hormone Is Altered in Mice Null for β-Arrestin2
2005
Change in Bone Turnover and Hip, Non-Spine, and Vertebral Fracture in Alendronate-Treated Women: The Fracture Intervention Trial
2004
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis
2016
[Selective estrogen receptor modulators (SERM): new substances for hormone replacement therapy].
1999
Noninvasive assessment of bone mineral and structure: State of the art
1996
A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women
2004
Bone Resorption by Osteoclasts
2000 StandoutScience
Abnormal Vascular Function and Hypertension in Mice Deficient in Estrogen Receptor β
2002 StandoutScienceNobel
β-Arrestin2 Regulates the Differential Response of Cortical and Trabecular Bone to Intermittent PTH in Female Mice
2005
Selective Estrogen Receptor Modulators
2004
Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis
2007
The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women
2001
Prediction of Incident Hip Fracture with the Estimated Femoral Strength by Finite Element Analysis of DXA Scans in the Study of Osteoporotic Fractures
2014
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
2008
Relationship Between Changes in Biochemical Markers of Bone Turnover and BMD to Predict Vertebral Fracture Risk
2004
Screening for Osteoporosis: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation
2010
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
2006 Standout
Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis
2008
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
2017
The Molecular Pharmacology of SERMs
1999
In Vivo Magnetic Resonance Detects Rapid Remodeling Changes in the Topology of the Trabecular Bone Network After Menopause and the Protective Effect of Estradiol
2008
Cancer treatment and survivorship statistics, 2019
2019 Standout
Teriparatide [Human PTH(1-34)]: 2.5 Years of Experience on the Use and Safety of the Drug for the Treatment of Osteoporosis
2006
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
2002 Standout
Toremifene Increases Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase 3 Clinical Study
2007
Alendronate Prevents Further Bone Loss in Renal Transplant Recipients
2001
Differential Effects of Teriparatide and Alendronate on Bone Remodeling in Postmenopausal Women Assessed by Histomorphometric Parameters
2005
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance
2008
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis
2016
Clinical Applications of Vertebral Fracture Assessment by Dual-Energy X-Ray Absorptiometry
2006
Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents
2003
A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] with Alendronate in Postmenopausal Women with Osteoporosis
2002
Therapeutic Approaches to Bone Diseases
2000 Science
Bone Loss and Bone Size After Menopause
2004
Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor
1999 Standout
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
2006 StandoutScience
Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study
2017
Postmenopausal Osteoporosis
2016
Works of Bruce Mitlak being referenced
Beyond Hip: Importance of Other Nonspinal Fractures
2007
Long-term Effects of Raloxifene on Bone Mineral Density, Bone Turnover, and Serum Lipid Levels in Early Postmenopausal Women
2000
Parathyroid Hormone-Related Peptide Mediates Hypercalcemia in an Islet Cell Tumor of the Pancreas
1991
Six and Twelve Month Changes in Bone Turnover are Related to Reduction in Vertebral Fracture Risk During 3 Years of Raloxifene Treatment in Postmenopausal Osteoporosis
2001
Geographic Differences in Bone Turnover: Data from a Multinational Study in Healthy Postmenopausal Women
1998
The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures
2011
Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
1997 Standout
Sustained Vertebral Fracture Risk Reduction After Withdrawal of Teriparatide in Postmenopausal Women With Osteoporosis
2004
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
2001 Standout
Enhancement of Experimental Fracture-Healing by Systemic Administration of Recombinant Human Parathyroid Hormone (PTH 1-34)
2005
In Search of Optimal Long-Term Female Hormone Replacement: The Potential of Selective Estrogen Receptor Modulators
1997
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
2013
Parathyroid Function in Normocalcemic Renal Transplant Recipients: Evaluation by Calcium Infusion*
1991
Femoral strength in osteoporotic women treated with teriparatide or alendronate
2011
Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover
2006
Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure
2003
Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
1998
The Skeletal Response to Teriparatide Is Largely Independent of Age, Initial Bone Mineral Density, and Prevalent Vertebral Fractures in Postmenopausal Women With Osteoporosis
2003
Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy
2002
A comparison of lateral versus anterior-posterior spine dual energy x-ray absorptiometry for the diagnosis of osteopenia.
1994
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women
2010
Pamidronate Reduces PTH-mediated bone loss in a gene transfer model of hyperparathyroidism in rats
1991
Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-Year Randomized Clinical Trial
2000
Effectiveness of instant vertebral assessment to detect prevalent vertebral fracture
2006
The effect of systemically administered PDGF-BB on the rodent skeleton
1996
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women With Osteoporosis
2001
A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density
2014
Effects of Teriparatide and Alendronate on Vertebral Strength as Assessed by Finite Element Modeling of QCT Scans in Women With Osteoporosis
2006
Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures
2009
Sustained Nonvertebral Fragility Fracture Risk Reduction After Discontinuation of Teriparatide Treatment
2005